Get the Daily Brief
Latest Biotech News
Lyme vaccine shows 73% efficacy... misses statistical threshold
Pfizer and Valneva reported that their Lyme disease vaccine reduced cases by roughly 73% in a large Phase 3 trial but failed to meet the trial’s pre‑specified statistical threshold because the...
Diasorin commits €10M to US launch — pivots China strategy, shutters German plant
Diasorin said it will invest about €10 million to commercialize its Liaison Nes point‑of‑care PCR platform in the U.S., building a 30‑person sales force and partnering with Thermo Fisher and...
Congress hearing: BIO board member says China speeds trials, threatens US lead
Dr. Jacob Becraft, CEO of Strand Therapeutics and a member of the BIO board, told the House Select Committee on China that China’s biotech ecosystem has accelerated clinical trial...
Apogee’s long‑acting eczema drug shows durable control with infrequent dosing
Apogee Therapeutics released Phase 2 maintenance data showing its anti‑IL‑13 candidate zumilokibart maintained EASI‑75 skin responses with far less frequent dosing: 75% of patients on quarterly...
Insmed’s Arikayce wins late‑stage trial — eyes earlier use in MAC lung disease
Insmed announced a Phase 3 win showing that adding Arikayce to standard therapy improved respiratory symptoms and culture conversion in patients with newly diagnosed Mycobacterium avium complex...
Sanofi returns to T‑cell engagers with $1.2B pact for phase‑1 trispecific
Sanofi struck a deal to acquire rights to a phase‑1 trispecific T‑cell engager from Kali Therapeutics, providing $180 million upfront as part of a broader agreement that can reach roughly $1.2...
Crossbow raises $77M Series B — funds lead Phase I for CBX‑250
Crossbow Therapeutics closed a $77 million Series B to advance its T‑Bolt platform and support a Phase I trial of CBX‑250, a novel T‑cell engager targeting relapsed and refractory myeloid...
Novartis agrees up to $3B acquisition — picks up mutant‑selective PI3Kα asset SNV4818
Novartis agreed to acquire Pikavation Therapeutics for up to $3 billion to obtain SNV4818, a pan‑mutant selective PI3Kα inhibitor in early clinical testing for HR+/HER2‑ metastatic breast cancer...
Crossbow closes $77m Series B to push T‑cell engager into clinic
Crossbow Therapeutics closed a $77 million Series B to advance its T‑Bolt platform and complete the Phase I study of CBX‑250, the company said. CEO Briggs Morrison told BioXconomy the financing...
Novartis inks up to $3B deal for mutant‑selective PI3Kα program
Novartis agreed to acquire Pikavation Therapeutics for up to $3 billion to add SNV4818, a pan‑mutant selective PI3Kα inhibitor, to its oncology pipeline. Novartis framed the deal as a move to...
CytomX posts 32% ORR in mCRC dose expansion; shares roller‑coaster
CytomX reported positive dose‑expansion data for varsetatug masetecan (varseta‑M) in metastatic colorectal cancer, delivering a 32% overall response rate and median progression‑free survival of...
Reinforced biotubes unveiled as off‑the‑shelf regenerative vascular grafts
Researchers published reinforced biotubes in Nature Communications, describing a new class of regenerative vascular grafts engineered to mimic native vessel scaffolding and support host...
Alectinib plus CAR T shows synergy in ALK‑driven neuroblastoma models
Preclinical work found that the ALK inhibitor alectinib enhances CAR‑T cell cytotoxicity against ALK‑mutant neuroblastoma, the study reports. Investigators demonstrated improved tumor cell killing...
HKUST deciphers how DICER trims microRNAs with single‑nucleotide precision
A research team at The Hong Kong University of Science and Technology revealed the molecular mechanism by which human DICER processes microRNAs with single‑nucleotide accuracy. The work elucidates...
ADA2 deficiency linked to rampant cell death and metabolic collapse
A study in Cell Death Discovery reported that cells lacking adenosine deaminase 2 (ADA2) show markedly increased cell death accompanied by severe metabolic dysfunction. Authors mapped metabolic...
Acinetobacter capsule biology alters antibiotic resistance and host immunity
Researchers dissected how capsular polysaccharides in Acinetobacter species modulate drug resistance and immune evasion. The paper details capsule‑dependent effects on antibiotic penetration,...
New antimalarial dimers discovered in deep‑sea fungus
Scientists isolated two novel dimeric compounds, piperasagamines A and B, from a deep‑sea Aspergillus strain (FKJ‑0404) and reported antimalarial activity in early studies. The structures...
Pocket DART scope and Human Organ Atlas push faster, label‑free molecular imaging
Two imaging innovations promise to speed molecular mapping in biology and clinical research. A deep‑UV DART pocket‑scope delivers fast, label‑free imaging of DNA and proteins using deep‑UV light,...
Crossbow raises $77M to advance T‑cell engager program
Crossbow Therapeutics closed a $77 million Series B to advance its T‑cell engager pipeline, the company said. Cambridge, Massachusetts–based Crossbow will use the funds to complete a Phase I trial...
Novartis inks up to $3B deal for mutant‑selective PI3Kα asset
Novartis agreed to acquire Pikavation Therapeutics for up to $3 billion to add SNV4818, a mutant‑selective PI3Kα inhibitor, to its oncology pipeline. The deal includes roughly two‑thirds of the...